The Inflammasome in Atherosclerosis and Type 2 Diabetes
The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes and atherosclerosis might be linked through the inflammasome via obesity-related triggers.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Chronic, low-grade, systemic inflammation is a feature of type 2 diabetes, identifiable by the presence of circulating inflammatory markers [1, 2].”
From Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials (2022) · cites this paper as [1]
In the citing paper
“Elevated plasma glucose levels and dyslipidemia have been associated with proinflammatory cytokine production, suggesting a mechanistic link between type 2 diabetes, inflammation, and atherosclerotic cardiovascular (CV) disease [1, 2]”
From Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials (2022) · cites this paper as [1]
In the citing paper
“the hsCRP reduction observed with the GLP-1RA semaglutide suggests that it might exert anti-inflammatory effects.”
From Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials (2022) · cites this paper as [1]
Citations
Cites
1 retracted
Tsukumo, D. M. L., Carvalho-Filho, M. A., Carvalheira, J. B. C., Prada, P. O., Hirabara, S. M., Schenka, A. A., Araújo, E. P., Vassallo, J., Curi, R., Velloso, L. A., et al. (2007) · Diabetes · doi:10.2337/db06-1595 · Cited by 826
RetractedObesity is associated with macrophage accumulation in adipose tissue
Weisberg, S. P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R. L., & Ferrante, A. W. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200319246 · Cited by 10,041 · cited 1×
“Macrophages, which are intricately involved in in ammatory signaling pathways, in ltrate adipose tissue to a greater extent in obese relative to nonobese individuals (8).”
BackgroundHaffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Schroder, K., & Tschopp, J. (2010) · Cell · doi:10.1016/j.cell.2010.01.040 · Cited by 5,475
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026
Self-citationPyroptosis: host cell death and inflammation
Bergsbaken, T., Fink, S. L., & Cookson, B. T. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2070 · Cited by 3,183
Hornung, V., Bauernfeind, F., Halle, A., Samstad, E. O., Kono, H., Rock, K. L., Fitzgerald, K. A., & Latz, E. (2008) · Nature Immunology · doi:10.1038/ni.1631 · Cited by 3,065
Self-citationThioredoxin-interacting protein links oxidative stress to inflammasome activation
Zhou, R., Tardivel, A., Thorens, B., Choi, I., & Tschopp, J. (2010) · Nature Immunology · doi:10.1038/ni.1831 · Cited by 2,708
Innate Immune Activation Through Nalp3 Inflammasome Sensing of Asbestos and Silica
Dostert, C., Pétrilli, V., Van Bruggen, R., Steele, C., Mossman, B. T., & Tschopp, J. (2008) · Science · doi:10.1126/science.1156995 · Cited by 2,658
The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance
Vandanmagsar, B., Youm, Y.-H., Ravussin, A., Galgani, J. E., Stadler, K., Mynatt, R. L., Ravussin, E., Stephens, J. M., & Dixit, V. D. (2011) · Nature Medicine · doi:10.1038/nm.2279 · Cited by 2,655
The Inflammasomes: Guardians of the Body
Martinon, F., Mayor, A., & Tschopp, J. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132715 · Cited by 2,436
Mitochondrial dysfunction and type 2 diabetes
Lowell, B. B., & Shulman, G. I. (2005) · Science · doi:10.1126/science.1104343 · Cited by 2,070
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798
Stewart, C. R., Stuart, L. M., Wilkinson, K., van Gils, J. M., Deng, J., Halle, A., Rayner, K. J., Boyer, L., Zhong, R., Frazier, W. A., et al. (2010) · Nature Immunology · doi:10.1038/ni.1836 · Cited by 1,513
Inflammatory Cytokines and the Risk to Develop Type 2 Diabetes
Spranger, J., Kroke, A., Möhlig, M., Hoffmann, K., Bergmann, M. M., Ristow, M., Boeing, H., & Pfeiffer, A. F. H. (2003) · Diabetes · doi:10.2337/diabetes.52.3.812 · Cited by 1,493
Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration
Pétrilli, V, Papin, S., Dostert, C., Mayor, A., Martinon, F., & Tschopp, J. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402195 · Cited by 1,445
Masters, S. L., Dunne, A., Subramanian, S. L., Hull, R. L., Tannahill, G. M., Sharp, F. A., Becker, C., Franchi, L., Yoshihara, E., Chen, Z., et al. (2010) · Nature Immunology · doi:10.1038/ni.1935 · Cited by 1,330
Self-citationCooper, G. J., Willis, A. C., Clark, A., Turner, R. C., Sim, R. B., & Reid, K. B. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.23.8628 · Cited by 1,299
Lipid screening and cardiovascular health in childhood
Daniels, S. R., Greer, F. R., & and the Committee on Nutrition (2008) · Pediatrics · doi:10.1542/peds.2008-1349 · Cited by 1,178
Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92172 · Cited by 1,114
Is Type II diabetes mellitus a disease of the innate immune system?
Pickup, J. C., & Crook, M. A. (1998) · Diabetologia · doi:10.1007/s001250051058 · Cited by 1,041 · cited 1×
“Although atherosclerosis is typically thought of as an in ammatory disease, the arguments for in ammation in T2D have not been as widely propagated (7).”
BackgroundRajamäki, K., Lappalainen, J., Öörni, K., Välimäki, E., Matikainen, S., Kovanen, P. T., & Eklund, K. K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011765 · Cited by 1,039
Fernandes-Alnemri, T., Wu, J., Yu, J.-W., Datta, P., Miller, B., Jankowski, W., Rosenberg, S., Zhang, J., & Alnemri, E. S. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402194 · Cited by 1,026
Michelsen, K. S., Wong, M. H., Shah, P. K., Zhang, W., Yano, J., Doherty, T. M., Akira, S., Rajavashisth, T. B., & Arditi, M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403249101 · Cited by 1,019
Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215318 · Cited by 1,005
Zeiher, A. M., Drexler, H., Wollschläger, H., & Just, H. (1991) · Circulation · doi:10.1161/01.cir.83.2.391 · Cited by 995
Westermark, P., Wernstedt, C., Wilander, E., Hayden, D. W., O'Brien, T. D., & Johnson, K. H. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.11.3881 · Cited by 976
Glyburide inhibits the Cryopyrin/Nalp3 inflammasome
Lamkanfi, M., Mueller, J. L., Vitari, A. C., Misaghi, S., Fedorova, A., Deshayes, K., Lee, W. P., Hoffman, H. M., & Dixit, V. M. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200903124 · Cited by 820
Cruz, C. M., Rinna, A., Forman, H. J., Ventura, A. L. M., Persechini, P. M., & Ojcius, D. M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608083200 · Cited by 786
Increased Number of Islet-Associated Macrophages in Type 2 Diabetes
Ehses, J. A., Perren, A., Eppler, E., Ribaux, P., Pospisilik, J. A., Maor-Cahn, R., Gueripel, X., Ellingsgaard, H., Schneider, M. K. J., Biollaz, G., et al. (2007) · Diabetes · doi:10.2337/db06-1650 · Cited by 783 · cited 1×
“e number of islet macrophages might also be increased in T2D (76, 77).”
BackgroundLack of Interleukin-1β Decreases the Severity of Atherosclerosis in ApoE-Deficient Mice
Kirii, H., Niwa, T., Yamada, Y., Wada, H., Saito, K., Iwakura, Y., Asano, M., Moriwaki, H., & Seishima, M. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000064374.15232.c3 · Cited by 748
Activated platelets mediate inflammatory signaling by regulated interleukin 1β synthesis
Lindemann, S., Tolley, N. D., Dixon, D. A., McIntyre, T. M., Prescott, S. M., Zimmerman, G. A., & Weyrich, A. S. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.200105058 · Cited by 697
Ueki, K., Kondo, T., & Kahn, C. R. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.12.5434-5446.2004 · Cited by 686 · cited 1×
“Chronic systemic in ammation is one factor that contributes to insulin resistance via upregulation of SOCS (suppressor of cytokine signaling) proteins, which attenuate insulin receptor signaling (9, 10), and that a ects the vasculature owing to endothelial cell dysfunction (11, 12).”
BackgroundStienstra, R., Joosten, L. A. B., Koenen, T., van Tits, B., van Diepen, J. A., van den Berg, S. A. A., Rensen, P. C. N., Voshol, P. J., Fantuzzi, G., Hijmans, A., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.11.011 · Cited by 676
Expression of Interleukin-18 in Human Atherosclerotic Plaques and Relation to Plaque Instability
Mallat, Z., Corbaz, A., Scoazec, A., Besnard, S., Lesèche, G., Chvatchko, Y., & Tedgui, A. (2001) · Circulation · doi:10.1161/hc3901.096721 · Cited by 636 · cited 1×
“Similar to IL-1β, IL-18 is predominantly secreted by macrophages in the atherosclerotic plaque (49) and is also expressed in and functions on pancreatic islet cells (50).”
BackgroundToll-Like Receptor-4 Mediates Vascular Inflammation and Insulin Resistance in Diet-Induced Obesity
Kim, F., Pham, M., Luttrell, I., Bannerman, D. D., Tupper, J., Thaler, J., Hawn, T. R., Raines, E. W., & Schwartz, M. W. (2007) · Circulation Research · doi:10.1161/circresaha.106.142851 · Cited by 584
Interleukin-18 Is a Strong Predictor of Cardiovascular Death in Stable and Unstable Angina
Blankenberg, S., Tiret, L., Bickel, C., Peetz, D., Cambien, F., Meyer, J., & Rupprecht, H. J. (2002) · Circulation · doi:10.1161/01.cir.0000020546.30940.92 · Cited by 568 · cited 1×
“Plasma IL-18 concentrations are elevated in both T2D and atherosclerosis, and increased IL-18 is predictive of outcome, thus suggesting it has a pathogenic role (46, 47).”
BackgroundMutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome
Drenth, J. P. H., Cuisset, L., Grateau, G., Vasseur, C., van de Velde-Visser, S. D., de Jong, J. G. N., Beckmann, J. S., van der Meer, J. W. M., & Delpech & contributing members of t, M. (1999) · Nature Genetics · doi:10.1038/9696 · Cited by 556
Modulation of atherosclerosis in mice by Toll-like receptor 2
Mullick, A. E. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25482 · Cited by 549 · cited 1×
“It has been shown in mice that TLR2 is important for the progression of atherosclerosis independent of dietary lipids (19, 20) as well as for insulin resistance initiated by a high-fat diet (21).”
BackgroundCytotoxicity of Human p I 7 Interleukin-1 for Pancreatic Islets of Langerhans
Bendtzen, K., Mandrup-Poulsen, T., Nerup, J., Nielsen, J. H., Dinarello, C. A., & Svenson, M. (1986) · Science · doi:10.1126/science.3086977 · Cited by 529 · cited 1×
“An initial role for IL-1β in diabetes was identi ed because the cytokine can be toxic to pancreatic β cells (23).”
BackgroundCalver, A., Collier, J., & Vallance, P. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116149 · Cited by 522 · cited 1×
“Chronic systemic in ammation is one factor that contributes to insulin resistance via upregulation of SOCS (suppressor of cytokine signaling) proteins, which attenuate insulin receptor signaling (9, 10), and that a ects the vasculature owing to endothelial cell dysfunction (11, 12).”
BackgroundRollins, B. J., Yoshimura, T., Leonard, E. J., & Pober, J. S. (1990) · Europe PMC (PubMed Central) · Cited by 492
The inflammasomes: mechanisms of activation and function
Latz, E. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.12.004 · Cited by 460
Self-citationGeng, Y.-J., Wu, Q., Muszynski, M., Hansson, G. K., & Libby, P. (1996) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.16.1.19 · Cited by 434
Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes
Larsen, C. M., Faulenbach, M., Vaag, A., Ehses, J. A., Donath, M. Y., & Mandrup-Poulsen, T. (2009) · Diabetes Care · doi:10.2337/dc09-0533 · Cited by 401
Miller, Y. I., Viriyakosol, S., Binder, C. J., Feramisco, J. R., Kirkland, T. N., & Witztum, J. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209634200 · Cited by 399
Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller‐Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15318 · Cited by 363
Poggi, M., Bastelica, D., Gual, P., Iglesias, M. A., Gremeaux, T., Knauf, C., Peiretti, F., Verdier, M., Juhan-Vague, I., Tanti, J. F., et al. (2007) · Diabetologia · doi:10.1007/s00125-007-0654-8 · Cited by 355
IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat
Ehses, J. A., Lacraz, G., Giroix, M.-H., Schmidlin, F., Coulaud, J., Kassis, N., Irminger, J.-C., Kergoat, M., Portha, B., Homo-Delarche, F., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810087106 · Cited by 347
CATERPILLER: A Novel Gene Family Important in Immunity, Cell Death, and Diseases
Ting, J. P.-Y., & Davis, B. K. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115616 · Cited by 347 · cited 1×
“Instead, it has been postulated that these di erent agents might all be able to activate the same in ammasome by perturbing a common intracellular homeostatic parameter (55).”
BackgroundThorp, E., Li, G., Seimon, T. A., Kuriakose, G., Ron, D., & Tabas, I. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.03.003 · Cited by 340
Böni-Schnetzler, M., Boller, S., Debray, S., Bouzakri, K., Meier, D. T., Prazak, R., Kerr-Conte, J., Pattou, F., Ehses, J. A., Schuit, F. C., et al. (2009) · Endocrinology · doi:10.1210/en.2009-0543 · Cited by 339
Joosten, L. A. B., Netea, M. G., Mylona, E., Koenders, M. I., Malireddi, R. K. S., Oosting, M., Stienstra, R., van de Veerdonk, F. L., Stalenhoef, A. F., Giamarellos‐Bourboulis, E. J., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27667 · Cited by 328 · cited 1×
“Elevated amounts of FFAs are another metabolic insult that might activate TLRs and thus prime the in ammasome in these disease settings (86, 87).”
BackgroundRole of IL-1β in type 2 diabetes
Dinarello, C. A., Donath, M. Y., & Mandrup-Poulsen, T. (2010) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32833bf6dc · Cited by 327
Böni-Schnetzler, M., Thorne, J., Parnaud, G., Marselli, L., Ehses, J. A., Kerr-Conte, J., Pattou, F., Halban, P. A., Weir, G. C., & Donath, M. Y. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0396 · Cited by 320 · cited 2×
“It also appears that IL-1β production by β cells ex vivo in response to increased glucose might be technically challenging because di erent labs have varied results (65, 66, 68).”
BackgroundArterial Inflammation in Mice Lacking the Interleukin 1 Receptor Antagonist Gene
Nicklin, M. J. H., Hughes, D. E., Barton, J. L., Ure, J. M., & Duff, G. W. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.2.303 · Cited by 317
Interleukin-1β in Coronary Arteries of Patients With Ischemic Heart Disease
Galea, J., Armstrong, J., Gadsdon, P., Holden, H., Francis, S. E., & Holt, C. M. (1996) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.16.8.1000 · Cited by 310
Islet-associated macrophages in type 2 diabetes
Richardson, S. J., Willcox, A., Bone, A. J., Foulis, A. K., & Morgan, N. G. (2009) · Diabetologia · doi:10.1007/s00125-009-1410-z · Cited by 239
IL-1 produced and released endogenously within human islets inhibits beta cell function.
Arnush, M., Heitmeier, M. R., Scarim, A. L., Marino, M. H., Manning, P. T., & Corbett, J. A. (1998) · Journal of Clinical Investigation · doi:10.1172/jci844 · Cited by 237 · cited 1×
“Others have shown colocalization of IL-1β and macrophage cell markers in preparations of human islets (75).”
BackgroundSynthesis of IL-1 alpha and IL-1 beta by arterial cells in atherosclerosis.
Moyer, C. F., Sajuthi, D., Tulli, H. M., & Williams, J. K. (1991) · PubMed Central · Cited by 234
Ehses, J. A., Meier, D. T., Wueest, S., Rytka, J., Boller, S., Wielinga, P. Y., Schraenen, A., Lemaire, K., Debray, S., Van Lommel, L., et al. (2010) · Diabetologia · doi:10.1007/s00125-010-1747-3 · Cited by 222
Suppressor of Cytokine Signaling 3 Is a Physiological Regulator of Adipocyte Insulin Signaling
Shi, H., Tzameli, I., Bjørbæk, C., & Flier, J. S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403886200 · Cited by 222 · cited 1×
“Chronic systemic in ammation is one factor that contributes to insulin resistance via upregulation of SOCS (suppressor of cytokine signaling) proteins, which attenuate insulin receptor signaling (9, 10), and that a ects the vasculature owing to endothelial cell dysfunction (11, 12).”
BackgroundShalev, A., Pise-Masison, C. A., Radonovich, M., Hoffmann, S. C., Hirshberg, B., Brady, J. N., & Harlan, D. M. (2002) · Endocrinology · doi:10.1210/en.2002-220564 · Cited by 219
Elevated Levels of Interleukin-18 Predict the Development of Type 2 Diabetes
Thorand, B., Kolb, H., Baumert, J., Koenig, W., Chambless, L., Meisinger, C., Illig, T., Martin, S., & Herder, C. (2005) · Diabetes · doi:10.2337/diabetes.54.10.2932 · Cited by 216
Sauter, N. S., Schulthess, F. T., Galasso, R., Castellani, L. W., & Maedler, K. (2008) · Endocrinology · doi:10.1210/en.2007-1059 · Cited by 198
Zraika, S., Hull, R. L., Verchere, C. B., Clark, A., Potter, K. J., Fraser, P. E., Raleigh, D. P., & Kahn, S. E. (2010) · Diabetologia · doi:10.1007/s00125-010-1671-6 · Cited by 179 · cited 1×
“Actually, the cytotoxic species of IAPP might be soluble oligomers, which cannot be observed by staining for insoluble amyloid brils (74).”
BackgroundMehta, J. L., Rasouli, N., Sinha, A. K., & Molavi, B. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.12.008 · Cited by 168
Bodar, E. J., van der Hilst, J. C. H., Drenth, J. P. H., van der Meer, J. W. M., & Simon, A. (2005) · PubMed · Cited by 166
Liu, X., Ukai, T., Yumoto, H., Davey, M., Goswami, S., Gibson, F. C., & Genco, C. A. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.03.025 · Cited by 161 · cited 1×
“It has been shown in mice that TLR2 is important for the progression of atherosclerosis independent of dietary lipids (19, 20) as well as for insulin resistance initiated by a high-fat diet (21).”
BackgroundTreatment with an Interleukin 1 beta antibody improves glycemic control in diet-induced obesity
Osborn, O., Brownell, S. E., Sanchez-Alavez, M., Salomon, D., Gram, H., & Bartfai, T. (2008) · Cytokine · doi:10.1016/j.cyto.2008.07.004 · Cited by 160
Longitudinal studies on the development of diabetes in individual Macaca nigra
Howard, C. F. (1986) · Diabetologia · doi:10.1007/bf00452067 · Cited by 141 · cited 1×
“In favor of a pathogenic role of IAPP, studies in primates closely match amyloid deposition with the severity of disease (73).”
BackgroundWelsh, N., Cnop, M., Kharroubi, I., Bugliani, M., Lupi, R., Marchetti, P., & Eizirik, D. L. (2005) · Diabetes · doi:10.2337/diabetes.54.11.3238 · Cited by 138
Westermann, D., Linthout, S. V., Dhayat, S. A., Dhayat, N. A., Escher, F., Bücker-Gärtner, C., Spillmann, F., Noutsias, M., Riad, A., Schultheiß, H., et al. (2007) · Diabetes · doi:10.2337/db06-1662 · Cited by 134
Ling, P. R., Bistrian, B. R., Mendez, B., & Istfan, N. W. (1994) · Metabolism · doi:10.1016/0026-0495(94)90093-0 · Cited by 128
Interleukin 1 affects glucose homeostasis
del Rey, A., & Besedovsky, H. O. (1987) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1987.253.5.r794 · Cited by 128
Decreased Fat Mass in Interleukin-1 Receptor Antagonist–Deficient Mice
Somm, E., Henrichot, E., Pernin, A., Juge-Aubry, C. E., Muzzin, P., Dayer, J.-M., Nicklin, M. J. H., & Meier, C. A. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3503 · Cited by 114
de Nooijer, R., von der Thüsen, J. H., Verkleij, C. J. N., Kuiper, J., Jukema, J. W., van der Wall, E. E., van Berkel, T. J. C., & Biessen, E. A. L. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000147126.99529.0a · Cited by 97
Owyang, A. M., Maedler, K., Gross, L., Yin, J., Esposito, L., Shu, L., Jadhav, J., Domsgen, E., Bergemann, J., Lee, S., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1124 · Cited by 95
Interleukin-18 genetics and inflammatory disease susceptibility
Thompson, S. R., & Humphries, S. E. (2007) · Genes and Immunity · doi:10.1038/sj.gene.6364366 · Cited by 94
Olofsson, P. S., Sheikine, Y., Jatta, K., Ghaderi, M., Samnegård, A., Eriksson, P. O., & Sirsjö, A. (2009) · Circulation Journal · doi:10.1253/circj.cj-08-1150 · Cited by 78
Eizirik, D. L., Strandell, E., Benutzen, K., & Sandler, S. (1988) · Diabetes · doi:10.2337/diab.37.7.916 · Cited by 58 · cited 1×
“To highlight this dichotomy, small amounts of IL-1β are actually hypoglycemic, although chronic administration decreases the rate of glucose oxidation in pancreatic islets, contributing to hyperglycemia (28).”
BackgroundA Stress-Induced, Superoxide-Mediated Caspase-1 Activation Pathway Causes Plasma IL-18 Upregulation
Sekiyama, A., Ueda, H., Kashiwamura, S., Sekiyama, R., Takeda, M., Rokutan, K., & Okamura, H. (2005) · Immunity · doi:10.1016/j.immuni.2005.04.006 · Cited by 56
Lewis, E. C., & Dinarello, C. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607917103 · Cited by 53
Venieratos, P. D., Drossopoulou, G. I., Kapodistria, K., Tsilibary, E. C., & Kitsiou, P. V. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.01.003 · Cited by 48
Bessler, H., Salman, H., Bergman, M., Straussberg, R., & Djaldetti, M. (2005) · Clinical Immunology · doi:10.1016/j.clim.2005.06.014 · Cited by 47
Tan, H., Liu, X., Bi, X., Xing, S., Li, L., Gong, H., Zhong, M., Wang, Z., Zhang, Y., & Zhang, W. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.07.053 · Cited by 44
Wogensen, L., Reimers, J., Nerup, J., -Bachofen, V. K., Kr�ncke, K. D., Almdal, T., & Mandrup-Poulsen, T. R. (1992) · Diabetologia · doi:10.1007/bf00401200 · Cited by 28
Lamacchia, C., Palmer, G., Bischoff, L., Rodriguez, E., Talabot‐Ayer, D., & Gabay, C. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000872 · Cited by 26
The Effects of Interleukin 1 on Myocardial Function and Metabolism
Hosenpud, J. D. (1993) · Clinical Immunology and Immunopathology · doi:10.1006/clin.1993.1115 · Cited by 24
Apolinário, E., Ferderbar, S., Pereira, E. C., Bertolami, M. C., Faludi, A. Á., Monte, O., Gagliardi, A. R. D. T., Xavier, H. T., & Abdalla, D. S. P. (2006) · Cited by 17
Eizirik, D. L., Strandell, E., Bendtzen, K., et al. (1988) · Diabetes · doi:10.2337/diabetes.37.7.916 · Cited by 14
Research works printed but not linked: 1
- 10.1038/ni.1831 · DOI · Paper page
Cited by
Inflammasomes: mechanism of action, role in disease, and therapeutics
Guo, H., Callaway, J. B., & Ting, J. P.-Y. (2015) · Nature Medicine · doi:10.1038/nm.3893 · Cited by 3,340
Tan, Y., Zhang, Z., Zheng, C., Wintergerst, K. A., Keller, B. B., & Cai, L. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0339-2 · Cited by 835
Upregulated NLRP3 Inflammasome Activation in Patients With Type 2 Diabetes
Lee, H.-M., Kim, J.-J., Kim, H. J., Shong, M., Ku, B. J., & Jo, E.-K. (2013) · Diabetes · doi:10.2337/db12-0420 · Cited by 734
“Recent studies have indicated that mitochondria, as the main source of inflammasome-activating ROS, deliver signals for activation of the NLRP3 inflammasome (18,30).”
BackgroundAutophagy Links Inflammasomes to Atherosclerotic Progression
Razani, B., Feng, C., Coleman, T., Emanuel, R., Wen, H., Hwang, S., Ting, J. P., Virgin, H. W., Kastan, M. B., & Semenkovich, C. F. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.02.011 · Cited by 601
“Lysosomal destabilization, which promotes inflammasome activation, has been reported when poorly digestible extracellular particulate matter (including cholesterol crystals) is phagocytosed and shuttled to lysosomes for degradation (Duewell et al., 2010; Hornung et al., 2008; Masters et al., 2011).”
Orchestration of Metabolism by Macrophages
Biswas, S. K., & Mantovani, A. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2011.11.013 · Cited by 586
“Saturated FFAs or elevated glucose levels activate TLRs in macrophages and adipocytes, triggering an inflamma- tory cascade (Masters et al., 2011) (Figure 2).”
BackgroundInfluential
Metadata
- Authors
- Masters, S. L., Latz, E., & O’Neill, L. A. J.
- Affiliations
- Trinity College Dublin (IE)
- University of Bonn (DE)
- Immunology Research Centre, Inflammation Research Group, School of Biochemistry and Immunology, Trinity College Dublin, 2 Dublin, Ireland.
- Corresponding author
- Masters, Seth L.
- Venue
- Science Translational Medicine
- Published
- 2011-05-04
- Volume
- 3
- Issue
- 81
- Pages
- 81ps17-81ps17
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2167915346
- Cited by
- 169
- References
- 89
- Citations by year
- 2026: 7 · 2025: 5 · 2024: 5 · 2023: 6 · 2022: 9 · 2021: 8 · 2020: 20 · 2019: 8 · 2018: 13 · 2017: 12 · 2016: 10 · 2015: 14 · 2014: 19 · 2013: 15 · 2012: 15
- FWCI
- 6.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL093262)
- National Institute of Allergy and Infectious Diseases (R01AI083713)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- inflammasome, atherosclerosis, type 2 diabetes, IL-1β, IL-18, inflammation, cholesterol crystals, hyperglycemia, ceramide, amylin, obesity, IL-1β inhibitors
- MeSH terms
- Animals, Diabetes Mellitus, Type 2, Humans, Interleukin-18, Atherosclerosis, Interleukin-1beta, Inflammasomes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.